(6-Mercaptopurine-9-β-D-ribofuranoside)-5'-phosphoric acid (3-dodecylmercapto-2-decyloxy)propyl ester

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (6-Mercaptopurine-9-β-D-ribofuranoside)-5'-phosphoric acid (3-dodecylmercapto-2-decyloxy)propyl ester
• 英文别名: [(2R,3S,4R,5S)-3,4-dihydroxy-5-[(6-sulfanylidene-3H-purin-9-yl)oxy]oxolan-2-yl]methyl 3-(3-dodecylsulfanyldecan-2-yloxy)propyl hydrogen phosphate
• 化学式: C₃₅H₆₃N₄O₉PS₂
• 分子量: 779.012
• InChiKey: GIIIFMMYGNBDAE-LDNGKXMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  51
• 可旋转键数：
  30
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  224
• 氢给体数：
  4
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  2,4,6-三异丙基苯磺酰氯 、 phosphoric acid mono(3-dodecylmercapto-2-decyloxy)-1-propyl ester 、 6-mercaptopurine riboside 、 calcium acetate 以 水 为溶剂， 生成 (6-Mercaptopurine-9-β-D-ribofuranoside)-5'-phosphoric acid (3-dodecylmercapto-2-decyloxy)propyl ester
  参考文献：
  名称：

  Lipid esters of nucleoside monophosphates and their use as

  摘要：

  本发明涉及一种新的核苷酸单磷酸脂酯残基的衍生物，其通式为(I)其中R.sup.1代表具有1-20个碳原子的可选择取代的烷基链；R.sup.2代表氢，一个具有1-20个碳原子的可选择取代的烷基链；R.sup.3、R.sup.4和R.sup.5代表氢，羟基，叠氮基，氨基，氰基或卤素；X代表一个价键，氧，硫，亚砜基或磺酰基；Y代表一个价键，一个氧或硫原子；B代表嘌呤和/或嘧啶碱基；但规定R.sup.3或R.sup.5中至少有一个残基为氢；它们的互变异构体及其生理上可接受的无机和有机酸和/或碱盐，以及其制备方法和含有所述化合物的药物。

  公开号：

  US06025343A1

文献信息

• LIPID CLEAVAGE ENZYME
  申请人：——

  公开号：US20020106363A1

  公开（公告）日：2002-08-08

  A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.

  一种尚未在现代技术中描述的膜酶可以从血液白细胞或单核/巨噬细胞的细胞膜分离物中提取。还公开了使用该酶底物制备含有这些底物作为药物活性成分的药物的用途。这些药物可用于将药理活性物质定向到目标细胞并用该物质富集目标细胞。还公开了含有该酶的体外研究系统，用于检测该酶的其他底物。
• Lapid cleavage enzyme
  申请人：Heidelberg Pharma Holding GmbH

  公开号：US20030082167A1

  公开（公告）日：2003-05-01

  A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.

  可以从血液白细胞或单核细胞/巨噬细胞的细胞膜分馏物中提取一种尚未在最新技术中描述的膜酶。 还公开了利用这种酶的底物制备含有这些底物作为药用活性物质的药物。 这些药剂可将药理活性物质导向靶细胞，并用上述物质富集靶细胞。 还公开了含有这种酶的体外研究系统，用于检测这种酶的其它底物。
• US7176011B2
  申请人：——

  公开号：US7176011B2

  公开（公告）日：2007-02-13
• Lipid esters of nucleoside monophosphates and their use as
  申请人：Roche Diagnostics GmbH

  公开号：US06025343A1

  公开（公告）日：2000-02-15

  The present invention is directed to new nucleoside monophosphate derivatives of lipid ester residues of general formula (I) ##STR1## wherein R.sup.1 represents an optionally substituted alkyl chain having 1-20 carbon atoms; R.sup.2 represents hydrogen, an optionally substituted alkyl chain having 1-20 carbon atoms; R.sup.3, R.sup.4 and R.sup.5 represent hydrogen, hydroxy, azido, amino, cyano, or halogen; X represents a valence dash, oxygen, sulfur, a sulfinyl or sulfonyl group; Y represents a valence dash, an oxygen or sulfur atom; B represents a purine and/or pyrimidine base; with the proviso that at least one of the residues R.sup.3 or R.sup.5 is hydrogen; to their tautomers and their physiologically acceptable salts of inorganic and organic acids and/or bases, as well as to processes for their preparation, and to drugs containing said compounds.

  本发明涉及一种新的核苷酸单磷酸脂酯残基的衍生物，其通式为(I)其中R.sup.1代表具有1-20个碳原子的可选择取代的烷基链；R.sup.2代表氢，一个具有1-20个碳原子的可选择取代的烷基链；R.sup.3、R.sup.4和R.sup.5代表氢，羟基，叠氮基，氨基，氰基或卤素；X代表一个价键，氧，硫，亚砜基或磺酰基；Y代表一个价键，一个氧或硫原子；B代表嘌呤和/或嘧啶碱基；但规定R.sup.3或R.sup.5中至少有一个残基为氢；它们的互变异构体及其生理上可接受的无机和有机酸和/或碱盐，以及其制备方法和含有所述化合物的药物。